sample_name	library_ID	title	library_strategy	library_source	library_selection	library_layout	platform	instrument_model	design_description	filetype	filename
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_01_100_1_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_01_100_1_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Belinostat (PXD101)	E1504_01_100_1_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_01_100_1_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Danusertib (PHA-739358)	E1504_01_100_1_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_01_100_1_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SNS-314 Mesylate	E1504_01_100_1_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_01_100_1_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM JNJ-7706621	E1504_01_100_1_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_01_100_1_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT129202	E1504_01_100_1_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_01_100_1_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-14361	E1504_01_100_1_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_01_100_1_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A HCl	E1504_01_100_1_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_01_100_1_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-907	E1504_01_100_1_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_01_100_1_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CI994 (Tacedinaline)	E1504_01_100_1_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_01_100_1_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entacapone	E1504_01_100_1_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_01_100_1_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_01_100_1_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_01_100_1_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_01_100_1_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_01_100_1_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Iniparib (BSI-201)	E1504_01_100_1_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_01_100_1_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Mocetinostat (MGCD0103)	E1504_01_100_1_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_01_100_1_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid sodium salt (Sodium valproate)	E1504_01_100_1_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_01_100_1_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Ruxolitinib (INCB018424)	E1504_01_100_1_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_01_100_1_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Hesperadin	E1504_01_100_1_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_01_100_1_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LY2784544	E1504_01_100_1_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_01_100_1_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NVP-BSK805 2HCl	E1504_01_100_1_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_01_100_1_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MK-5108 (VX-689)	E1504_01_100_1_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_01_100_1_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG108	E1504_01_100_1_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_01_100_1_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sodium Phenylbutyrate	E1504_01_100_1_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_01_100_1_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_01_100_1_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_01_100_1_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_01_100_1_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_01_100_1_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-24781 (Abexinostat)	E1504_01_100_1_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_01_100_1_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SRT1720	E1504_01_100_1_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_01_100_1_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYC116	E1504_01_100_1_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_01_100_1_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resveratrol	E1504_01_100_1_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_01_100_1_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EX 527 (Selisistat)	E1504_01_100_1_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_01_100_1_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1776 free base	E1504_01_100_1_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_01_100_1_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101209	E1504_01_100_1_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_01_100_1_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM M344	E1504_01_100_1_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_01_100_1_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Baricitinib (LY3009104, INCB028050)	E1504_01_100_1_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_01_100_1_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine (2-PCPA) HCl	E1504_01_100_1_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_01_100_1_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_01_100_1_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_01_100_1_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_01_100_1_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_01_100_1_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LAQ824 (Dacinostat)	E1504_01_100_1_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_01_100_1_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM INO-1001	E1504_01_100_1_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_01_100_1_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ENMD-2076	E1504_01_100_1_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_01_100_1_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Droxinostat	E1504_01_100_1_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_01_100_1_1_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Azacitidine	E1504_01_100_1_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_01_100_1_1_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZ 960	E1504_01_100_1_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_01_100_1_1_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resminostat	E1504_01_100_1_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_01_100_1_1_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET151 (GSK1210151A)	E1504_01_100_1_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_01_100_1_1_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WHI-P154	E1504_01_100_1_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_01_100_1_1_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Aminobenzamide	E1504_01_100_1_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_01_100_1_1_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_01_100_1_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_01_100_1_1_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_01_100_1_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_01_100_1_1_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quisinostat (JNJ-26481585)	E1504_01_100_1_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_01_100_1_1_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Alisertib (MLN8237)	E1504_01_100_1_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_01_100_1_1_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-101	E1504_01_100_1_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_01_100_1_1_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aurora A Inhibitor I	E1504_01_100_1_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_01_100_1_1_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-34051	E1504_01_100_1_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_01_100_1_1_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYT387	E1504_01_100_1_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_01_100_1_1_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TAK-901	E1504_01_100_1_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_01_100_1_1_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550,Tasocitinib)	E1504_01_100_1_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_01_100_1_1_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34	E1504_01_100_1_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_01_100_1_1_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Procainamide HCl	E1504_01_100_1_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_01_100_1_1_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_01_100_1_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_01_100_1_1_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_01_100_1_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_01_100_1_1_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rucaparib (AG-014699,PF-01367338)	E1504_01_100_1_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_01_100_1_1_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AT9283	E1504_01_100_1_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_01_100_1_1_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Decitabine	E1504_01_100_1_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_01_100_1_1_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PHA-680632	E1504_01_100_1_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_01_100_1_1_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM KW-2449	E1504_01_100_1_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_01_100_1_1_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubacin	E1504_01_100_1_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_01_100_1_1_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AMG-900	E1504_01_100_1_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_01_100_1_1_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WP1066	E1504_01_100_1_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_01_100_1_1_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM S-Ruxolitinib (INCB018424)	E1504_01_100_1_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_01_100_1_1_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550) Citrate	E1504_01_100_1_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_01_100_1_1_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_01_100_1_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_01_100_1_1_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_01_100_1_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_01_100_1_1_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MLN8054	E1504_01_100_1_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_01_100_1_1_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-490 (Tyrphostin B42)	E1504_01_100_1_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_01_100_1_1_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PFI-1 (PF-6405761)	E1504_01_100_1_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_01_100_1_1_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC1568	E1504_01_100_1_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_01_100_1_1_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1480	E1504_01_100_1_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_01_100_1_1_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AR-42	E1504_01_100_1_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_01_100_1_1_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101348 (SAR302503)	E1504_01_100_1_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_01_100_1_1_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sirtinol	E1504_01_100_1_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_01_100_1_1_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX2	E1504_01_100_1_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_01_100_1_1_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD2461	E1504_01_100_1_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_01_100_1_1_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_01_100_1_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_01_100_1_1_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_01_100_1_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_01_100_1_1_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 447439	E1504_01_100_1_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_01_100_1_1_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Barasertib (AZD1152-HQPA)	E1504_01_100_1_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_01_100_1_1_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2-Methoxyestradiol (2-MeOE2)	E1504_01_100_1_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_01_100_1_1_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pracinostat (SB939)	E1504_01_100_1_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_01_100_1_1_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Givinostat (ITF2357)	E1504_01_100_1_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_01_100_1_1_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quercetin	E1504_01_100_1_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_01_100_1_1_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT137690	E1504_01_100_1_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_01_100_1_1_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CEP-33779	E1504_01_100_1_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_01_100_1_1_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Romidepsin (FK228, Depsipeptide)	E1504_01_100_1_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_01_100_1_1_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM XL019	E1504_01_100_1_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_01_100_1_1_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_01_100_1_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_01_100_1_1_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_02_100_1_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_02_100_1_2_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Zebularine	E1504_02_100_1_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_02_100_1_2_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OG-L002	E1504_02_100_1_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_02_100_1_2_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TMP269	E1504_02_100_1_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_02_100_1_2_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 39923 HCl	E1504_02_100_1_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_02_100_1_2_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Veliparib (ABT-888)	E1504_02_100_1_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_02_100_1_2_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CX-6258 HCl	E1504_02_100_1_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_02_100_1_2_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2,4-Pyridinedicarboxylic Acid	E1504_02_100_1_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_02_100_1_2_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ITSA-1	E1504_02_100_1_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_02_100_1_2_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AGK2	E1504_02_100_1_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_02_100_1_2_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Oxamflatin	E1504_02_100_1_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_02_100_1_2_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_02_100_1_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_02_100_1_2_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_02_100_1_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_02_100_1_2_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Deazaneplanocin A (DZNeP)	E1504_02_100_1_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_02_100_1_2_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC-CBP30	E1504_02_100_1_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_02_100_1_2_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ004777	E1504_02_100_1_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_02_100_1_2_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SMI-4a	E1504_02_100_1_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_02_100_1_2_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM FG-4592	E1504_02_100_1_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_02_100_1_2_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BMN 673	E1504_02_100_1_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_02_100_1_2_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Garcinol	E1504_02_100_1_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_02_100_1_2_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine hemisulfate	E1504_02_100_1_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_02_100_1_2_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Salermide	E1504_02_100_1_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_02_100_1_2_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suramin 6Na	E1504_02_100_1_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_02_100_1_2_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_02_100_1_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_02_100_1_2_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_02_100_1_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_02_100_1_2_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ-6438	E1504_02_100_1_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_02_100_1_2_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MM-102	E1504_02_100_1_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_02_100_1_2_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OTX015	E1504_02_100_1_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_02_100_1_2_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX 01294	E1504_02_100_1_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_02_100_1_2_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Panobinostat (LBH589)	E1504_02_100_1_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_02_100_1_2_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ5676	E1504_02_100_1_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_02_100_1_2_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Splitomicin	E1504_02_100_1_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_02_100_1_2_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid	E1504_02_100_1_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_02_100_1_2_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC-1293	E1504_02_100_1_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_02_100_1_2_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-278	E1504_02_100_1_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_02_100_1_2_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_02_100_1_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_02_100_1_2_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_02_100_1_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_02_100_1_2_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM C646	E1504_02_100_1_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_02_100_1_2_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1027	E1504_02_100_1_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_02_100_1_2_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC669	E1504_02_100_1_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_02_100_1_2_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UPF 1069	E1504_02_100_1_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_02_100_1_2_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Trichostatin A (TSA)	E1504_02_100_1_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_02_100_1_2_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM GSK J4 HCl	E1504_02_100_1_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_02_100_1_2_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-210	E1504_02_100_1_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_02_100_1_2_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nicotinamide	E1504_02_100_1_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_02_100_1_2_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Anacardic acid	E1504_02_100_1_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_02_100_1_2_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NCH-51	E1504_02_100_1_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_02_100_1_2_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_02_100_1_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_02_100_1_2_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_02_100_1_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_02_100_1_2_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET-762	E1504_02_100_1_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_02_100_1_2_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG2833 (RGFP109)	E1504_02_100_1_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_02_100_1_2_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ME0328	E1504_02_100_1_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_02_100_1_2_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Scriptaid	E1504_02_100_1_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_02_100_1_2_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Vorinostat (SAHA, MK0683)	E1504_02_100_1_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_02_100_1_2_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC 0946	E1504_02_100_1_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_02_100_1_2_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Apicidin	E1504_02_100_1_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_02_100_1_2_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-266	E1504_02_100_1_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_02_100_1_2_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM B2	E1504_02_100_1_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_02_100_1_2_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NSC-3852	E1504_02_100_1_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_02_100_1_2_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_02_100_1_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_02_100_1_2_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_02_100_1_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_02_100_1_2_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RGFP966	E1504_02_100_1_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_02_100_1_2_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RVX-208	E1504_02_100_1_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_02_100_1_2_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nexturastat A	E1504_02_100_1_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_02_100_1_2_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A	E1504_02_100_1_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_02_100_1_2_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM VX-680 (Tozasertib, MK-0457)	E1504_02_100_1_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_02_100_1_2_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC1215	E1504_02_100_1_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_02_100_1_2_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suberoyl bis-hydroxamic acid	E1504_02_100_1_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_02_100_1_2_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Piceatannol	E1504_02_100_1_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_02_100_1_2_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX-01294 3HCl	E1504_02_100_1_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_02_100_1_2_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aminoresveratrol sulfate	E1504_02_100_1_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_02_100_1_2_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_02_100_1_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_02_100_1_2_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_02_100_1_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_02_100_1_2_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Bromosporine	E1504_02_100_1_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_02_100_1_2_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34 HCl	E1504_02_100_1_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_02_100_1_2_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Filgotinib (GLPG0634)	E1504_02_100_1_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_02_100_1_2_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Lomeguatrib	E1504_02_100_1_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_02_100_1_2_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entinostat (MS-275)	E1504_02_100_1_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_02_100_1_2_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1208	E1504_02_100_1_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_02_100_1_2_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nullscript	E1504_02_100_1_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_02_100_1_2_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Fluoro-SAHA	E1504_02_100_1_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_02_100_1_2_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Butyrolactone 3	E1504_02_100_1_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_02_100_1_2_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-281	E1504_02_100_1_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_02_100_1_2_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_02_100_1_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_02_100_1_2_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_02_100_1_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_02_100_1_2_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX1	E1504_02_100_1_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_02_100_1_2_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CPI-203	E1504_02_100_1_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_02_100_1_2_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rocilinostat (ACY-1215)	E1504_02_100_1_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_02_100_1_2_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pacritinib (SB1518)	E1504_02_100_1_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_02_100_1_2_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Olaparib (AZD2281, Ku-0059436)	E1504_02_100_1_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_02_100_1_2_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM (+)-JQ1	E1504_02_100_1_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_02_100_1_2_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Isonicotinamide	E1504_02_100_1_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_02_100_1_2_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid hydroxamate	E1504_02_100_1_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_02_100_1_2_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CTPB	E1504_02_100_1_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_02_100_1_2_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Triacetylresveratrol	E1504_02_100_1_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_02_100_1_2_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_02_100_1_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_02_100_1_2_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_03_100_2_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_03_100_2_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Belinostat (PXD101)	E1504_03_100_2_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_03_100_2_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Danusertib (PHA-739358)	E1504_03_100_2_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_03_100_2_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SNS-314 Mesylate	E1504_03_100_2_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_03_100_2_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM JNJ-7706621	E1504_03_100_2_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_03_100_2_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT129202	E1504_03_100_2_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_03_100_2_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-14361	E1504_03_100_2_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_03_100_2_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A HCl	E1504_03_100_2_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_03_100_2_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-907	E1504_03_100_2_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_03_100_2_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CI994 (Tacedinaline)	E1504_03_100_2_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_03_100_2_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entacapone	E1504_03_100_2_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_03_100_2_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_03_100_2_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_03_100_2_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_03_100_2_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_03_100_2_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Iniparib (BSI-201)	E1504_03_100_2_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_03_100_2_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Mocetinostat (MGCD0103)	E1504_03_100_2_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_03_100_2_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid sodium salt (Sodium valproate)	E1504_03_100_2_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_03_100_2_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Ruxolitinib (INCB018424)	E1504_03_100_2_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_03_100_2_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Hesperadin	E1504_03_100_2_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_03_100_2_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LY2784544	E1504_03_100_2_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_03_100_2_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NVP-BSK805 2HCl	E1504_03_100_2_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_03_100_2_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MK-5108 (VX-689)	E1504_03_100_2_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_03_100_2_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG108	E1504_03_100_2_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_03_100_2_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sodium Phenylbutyrate	E1504_03_100_2_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_03_100_2_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_03_100_2_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_03_100_2_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_03_100_2_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_03_100_2_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-24781 (Abexinostat)	E1504_03_100_2_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_03_100_2_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SRT1720	E1504_03_100_2_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_03_100_2_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYC116	E1504_03_100_2_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_03_100_2_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resveratrol	E1504_03_100_2_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_03_100_2_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EX 527 (Selisistat)	E1504_03_100_2_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_03_100_2_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1776 free base	E1504_03_100_2_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_03_100_2_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101209	E1504_03_100_2_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_03_100_2_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM M344	E1504_03_100_2_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_03_100_2_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Baricitinib (LY3009104, INCB028050)	E1504_03_100_2_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_03_100_2_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine (2-PCPA) HCl	E1504_03_100_2_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_03_100_2_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_03_100_2_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_03_100_2_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_03_100_2_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_03_100_2_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LAQ824 (Dacinostat)	E1504_03_100_2_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_03_100_2_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM INO-1001	E1504_03_100_2_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_03_100_2_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ENMD-2076	E1504_03_100_2_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_03_100_2_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Droxinostat	E1504_03_100_2_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_03_100_2_1_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Azacitidine	E1504_03_100_2_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_03_100_2_1_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZ 960	E1504_03_100_2_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_03_100_2_1_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resminostat	E1504_03_100_2_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_03_100_2_1_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET151 (GSK1210151A)	E1504_03_100_2_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_03_100_2_1_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WHI-P154	E1504_03_100_2_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_03_100_2_1_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Aminobenzamide	E1504_03_100_2_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_03_100_2_1_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_03_100_2_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_03_100_2_1_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_03_100_2_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_03_100_2_1_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quisinostat (JNJ-26481585)	E1504_03_100_2_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_03_100_2_1_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Alisertib (MLN8237)	E1504_03_100_2_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_03_100_2_1_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-101	E1504_03_100_2_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_03_100_2_1_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aurora A Inhibitor I	E1504_03_100_2_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_03_100_2_1_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-34051	E1504_03_100_2_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_03_100_2_1_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYT387	E1504_03_100_2_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_03_100_2_1_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TAK-901	E1504_03_100_2_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_03_100_2_1_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550,Tasocitinib)	E1504_03_100_2_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_03_100_2_1_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34	E1504_03_100_2_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_03_100_2_1_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Procainamide HCl	E1504_03_100_2_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_03_100_2_1_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_03_100_2_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_03_100_2_1_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_03_100_2_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_03_100_2_1_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rucaparib (AG-014699,PF-01367338)	E1504_03_100_2_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_03_100_2_1_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AT9283	E1504_03_100_2_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_03_100_2_1_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Decitabine	E1504_03_100_2_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_03_100_2_1_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PHA-680632	E1504_03_100_2_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_03_100_2_1_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM KW-2449	E1504_03_100_2_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_03_100_2_1_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubacin	E1504_03_100_2_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_03_100_2_1_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AMG-900	E1504_03_100_2_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_03_100_2_1_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WP1066	E1504_03_100_2_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_03_100_2_1_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM S-Ruxolitinib (INCB018424)	E1504_03_100_2_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_03_100_2_1_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550) Citrate	E1504_03_100_2_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_03_100_2_1_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_03_100_2_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_03_100_2_1_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_03_100_2_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_03_100_2_1_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MLN8054	E1504_03_100_2_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_03_100_2_1_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-490 (Tyrphostin B42)	E1504_03_100_2_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_03_100_2_1_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PFI-1 (PF-6405761)	E1504_03_100_2_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_03_100_2_1_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC1568	E1504_03_100_2_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_03_100_2_1_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1480	E1504_03_100_2_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_03_100_2_1_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AR-42	E1504_03_100_2_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_03_100_2_1_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101348 (SAR302503)	E1504_03_100_2_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_03_100_2_1_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sirtinol	E1504_03_100_2_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_03_100_2_1_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX2	E1504_03_100_2_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_03_100_2_1_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD2461	E1504_03_100_2_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_03_100_2_1_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_03_100_2_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_03_100_2_1_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_03_100_2_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_03_100_2_1_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 447439	E1504_03_100_2_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_03_100_2_1_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Barasertib (AZD1152-HQPA)	E1504_03_100_2_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_03_100_2_1_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2-Methoxyestradiol (2-MeOE2)	E1504_03_100_2_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_03_100_2_1_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pracinostat (SB939)	E1504_03_100_2_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_03_100_2_1_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Givinostat (ITF2357)	E1504_03_100_2_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_03_100_2_1_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quercetin	E1504_03_100_2_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_03_100_2_1_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT137690	E1504_03_100_2_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_03_100_2_1_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CEP-33779	E1504_03_100_2_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_03_100_2_1_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Romidepsin (FK228, Depsipeptide)	E1504_03_100_2_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_03_100_2_1_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM XL019	E1504_03_100_2_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_03_100_2_1_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_03_100_2_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_03_100_2_1_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_04_100_2_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_04_100_2_2_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Zebularine	E1504_04_100_2_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_04_100_2_2_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OG-L002	E1504_04_100_2_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_04_100_2_2_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TMP269	E1504_04_100_2_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_04_100_2_2_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 39923 HCl	E1504_04_100_2_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_04_100_2_2_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Veliparib (ABT-888)	E1504_04_100_2_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_04_100_2_2_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CX-6258 HCl	E1504_04_100_2_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_04_100_2_2_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2,4-Pyridinedicarboxylic Acid	E1504_04_100_2_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_04_100_2_2_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ITSA-1	E1504_04_100_2_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_04_100_2_2_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AGK2	E1504_04_100_2_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_04_100_2_2_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Oxamflatin	E1504_04_100_2_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_04_100_2_2_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_04_100_2_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_04_100_2_2_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_04_100_2_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_04_100_2_2_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Deazaneplanocin A (DZNeP)	E1504_04_100_2_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_04_100_2_2_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC-CBP30	E1504_04_100_2_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_04_100_2_2_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ004777	E1504_04_100_2_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_04_100_2_2_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SMI-4a	E1504_04_100_2_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_04_100_2_2_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM FG-4592	E1504_04_100_2_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_04_100_2_2_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BMN 673	E1504_04_100_2_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_04_100_2_2_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Garcinol	E1504_04_100_2_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_04_100_2_2_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine hemisulfate	E1504_04_100_2_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_04_100_2_2_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Salermide	E1504_04_100_2_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_04_100_2_2_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suramin 6Na	E1504_04_100_2_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_04_100_2_2_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_04_100_2_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_04_100_2_2_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_04_100_2_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_04_100_2_2_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ-6438	E1504_04_100_2_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_04_100_2_2_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MM-102	E1504_04_100_2_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_04_100_2_2_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OTX015	E1504_04_100_2_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_04_100_2_2_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX 01294	E1504_04_100_2_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_04_100_2_2_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Panobinostat (LBH589)	E1504_04_100_2_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_04_100_2_2_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ5676	E1504_04_100_2_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_04_100_2_2_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Splitomicin	E1504_04_100_2_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_04_100_2_2_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid	E1504_04_100_2_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_04_100_2_2_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC-1293	E1504_04_100_2_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_04_100_2_2_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-278	E1504_04_100_2_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_04_100_2_2_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_04_100_2_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_04_100_2_2_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_04_100_2_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_04_100_2_2_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM C646	E1504_04_100_2_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_04_100_2_2_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1027	E1504_04_100_2_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_04_100_2_2_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC669	E1504_04_100_2_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_04_100_2_2_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UPF 1069	E1504_04_100_2_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_04_100_2_2_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Trichostatin A (TSA)	E1504_04_100_2_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_04_100_2_2_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM GSK J4 HCl	E1504_04_100_2_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_04_100_2_2_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-210	E1504_04_100_2_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_04_100_2_2_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nicotinamide	E1504_04_100_2_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_04_100_2_2_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Anacardic acid	E1504_04_100_2_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_04_100_2_2_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NCH-51	E1504_04_100_2_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_04_100_2_2_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_04_100_2_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_04_100_2_2_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_04_100_2_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_04_100_2_2_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET-762	E1504_04_100_2_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_04_100_2_2_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG2833 (RGFP109)	E1504_04_100_2_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_04_100_2_2_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ME0328	E1504_04_100_2_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_04_100_2_2_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Scriptaid	E1504_04_100_2_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_04_100_2_2_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Vorinostat (SAHA, MK0683)	E1504_04_100_2_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_04_100_2_2_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC 0946	E1504_04_100_2_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_04_100_2_2_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Apicidin	E1504_04_100_2_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_04_100_2_2_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-266	E1504_04_100_2_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_04_100_2_2_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM B2	E1504_04_100_2_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_04_100_2_2_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NSC-3852	E1504_04_100_2_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_04_100_2_2_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_04_100_2_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_04_100_2_2_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_04_100_2_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_04_100_2_2_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RGFP966	E1504_04_100_2_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_04_100_2_2_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RVX-208	E1504_04_100_2_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_04_100_2_2_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nexturastat A	E1504_04_100_2_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_04_100_2_2_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A	E1504_04_100_2_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_04_100_2_2_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM VX-680 (Tozasertib, MK-0457)	E1504_04_100_2_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_04_100_2_2_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC1215	E1504_04_100_2_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_04_100_2_2_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suberoyl bis-hydroxamic acid	E1504_04_100_2_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_04_100_2_2_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Piceatannol	E1504_04_100_2_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_04_100_2_2_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX-01294 3HCl	E1504_04_100_2_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_04_100_2_2_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aminoresveratrol sulfate	E1504_04_100_2_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_04_100_2_2_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_04_100_2_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_04_100_2_2_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_04_100_2_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_04_100_2_2_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Bromosporine	E1504_04_100_2_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_04_100_2_2_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34 HCl	E1504_04_100_2_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_04_100_2_2_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Filgotinib (GLPG0634)	E1504_04_100_2_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_04_100_2_2_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Lomeguatrib	E1504_04_100_2_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_04_100_2_2_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entinostat (MS-275)	E1504_04_100_2_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_04_100_2_2_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1208	E1504_04_100_2_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_04_100_2_2_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nullscript	E1504_04_100_2_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_04_100_2_2_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Fluoro-SAHA	E1504_04_100_2_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_04_100_2_2_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Butyrolactone 3	E1504_04_100_2_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_04_100_2_2_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-281	E1504_04_100_2_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_04_100_2_2_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_04_100_2_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_04_100_2_2_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_04_100_2_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_04_100_2_2_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX1	E1504_04_100_2_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_04_100_2_2_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CPI-203	E1504_04_100_2_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_04_100_2_2_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rocilinostat (ACY-1215)	E1504_04_100_2_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_04_100_2_2_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pacritinib (SB1518)	E1504_04_100_2_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_04_100_2_2_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Olaparib (AZD2281, Ku-0059436)	E1504_04_100_2_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_04_100_2_2_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM (+)-JQ1	E1504_04_100_2_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_04_100_2_2_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Isonicotinamide	E1504_04_100_2_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_04_100_2_2_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid hydroxamate	E1504_04_100_2_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_04_100_2_2_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CTPB	E1504_04_100_2_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_04_100_2_2_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Triacetylresveratrol	E1504_04_100_2_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_04_100_2_2_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_04_100_2_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_04_100_2_2_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_05_100_3_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_05_100_3_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Belinostat (PXD101)	E1504_05_100_3_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_05_100_3_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Danusertib (PHA-739358)	E1504_05_100_3_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_05_100_3_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SNS-314 Mesylate	E1504_05_100_3_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_05_100_3_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM JNJ-7706621	E1504_05_100_3_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_05_100_3_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT129202	E1504_05_100_3_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_05_100_3_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-14361	E1504_05_100_3_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_05_100_3_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A HCl	E1504_05_100_3_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_05_100_3_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-907	E1504_05_100_3_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_05_100_3_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CI994 (Tacedinaline)	E1504_05_100_3_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_05_100_3_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entacapone	E1504_05_100_3_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_05_100_3_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_05_100_3_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_05_100_3_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_05_100_3_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_05_100_3_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Iniparib (BSI-201)	E1504_05_100_3_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_05_100_3_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Mocetinostat (MGCD0103)	E1504_05_100_3_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_05_100_3_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid sodium salt (Sodium valproate)	E1504_05_100_3_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_05_100_3_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Ruxolitinib (INCB018424)	E1504_05_100_3_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_05_100_3_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Hesperadin	E1504_05_100_3_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_05_100_3_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LY2784544	E1504_05_100_3_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_05_100_3_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NVP-BSK805 2HCl	E1504_05_100_3_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_05_100_3_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MK-5108 (VX-689)	E1504_05_100_3_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_05_100_3_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG108	E1504_05_100_3_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_05_100_3_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sodium Phenylbutyrate	E1504_05_100_3_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_05_100_3_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_05_100_3_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_05_100_3_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_05_100_3_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_05_100_3_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-24781 (Abexinostat)	E1504_05_100_3_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_05_100_3_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SRT1720	E1504_05_100_3_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_05_100_3_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYC116	E1504_05_100_3_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_05_100_3_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resveratrol	E1504_05_100_3_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_05_100_3_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EX 527 (Selisistat)	E1504_05_100_3_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_05_100_3_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1776 free base	E1504_05_100_3_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_05_100_3_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101209	E1504_05_100_3_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_05_100_3_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM M344	E1504_05_100_3_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_05_100_3_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Baricitinib (LY3009104, INCB028050)	E1504_05_100_3_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_05_100_3_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine (2-PCPA) HCl	E1504_05_100_3_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_05_100_3_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_05_100_3_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_05_100_3_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_05_100_3_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_05_100_3_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM LAQ824 (Dacinostat)	E1504_05_100_3_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_05_100_3_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM INO-1001	E1504_05_100_3_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_05_100_3_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ENMD-2076	E1504_05_100_3_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_05_100_3_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Droxinostat	E1504_05_100_3_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_05_100_3_1_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Azacitidine	E1504_05_100_3_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_05_100_3_1_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZ 960	E1504_05_100_3_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_05_100_3_1_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Resminostat	E1504_05_100_3_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_05_100_3_1_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET151 (GSK1210151A)	E1504_05_100_3_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_05_100_3_1_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WHI-P154	E1504_05_100_3_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_05_100_3_1_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Aminobenzamide	E1504_05_100_3_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_05_100_3_1_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_05_100_3_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_05_100_3_1_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_05_100_3_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_05_100_3_1_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quisinostat (JNJ-26481585)	E1504_05_100_3_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_05_100_3_1_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Alisertib (MLN8237)	E1504_05_100_3_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_05_100_3_1_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CUDC-101	E1504_05_100_3_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_05_100_3_1_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aurora A Inhibitor I	E1504_05_100_3_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_05_100_3_1_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PCI-34051	E1504_05_100_3_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_05_100_3_1_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CYT387	E1504_05_100_3_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_05_100_3_1_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TAK-901	E1504_05_100_3_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_05_100_3_1_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550,Tasocitinib)	E1504_05_100_3_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_05_100_3_1_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34	E1504_05_100_3_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_05_100_3_1_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Procainamide HCl	E1504_05_100_3_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_05_100_3_1_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_05_100_3_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_05_100_3_1_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_05_100_3_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_05_100_3_1_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rucaparib (AG-014699,PF-01367338)	E1504_05_100_3_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_05_100_3_1_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AT9283	E1504_05_100_3_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_05_100_3_1_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Decitabine	E1504_05_100_3_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_05_100_3_1_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PHA-680632	E1504_05_100_3_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_05_100_3_1_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM KW-2449	E1504_05_100_3_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_05_100_3_1_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubacin	E1504_05_100_3_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_05_100_3_1_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AMG-900	E1504_05_100_3_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_05_100_3_1_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM WP1066	E1504_05_100_3_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_05_100_3_1_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM S-Ruxolitinib (INCB018424)	E1504_05_100_3_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_05_100_3_1_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tofacitinib (CP-690550) Citrate	E1504_05_100_3_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_05_100_3_1_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_05_100_3_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_05_100_3_1_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_05_100_3_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_05_100_3_1_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MLN8054	E1504_05_100_3_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_05_100_3_1_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AG-490 (Tyrphostin B42)	E1504_05_100_3_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_05_100_3_1_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PFI-1 (PF-6405761)	E1504_05_100_3_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_05_100_3_1_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC1568	E1504_05_100_3_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_05_100_3_1_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1480	E1504_05_100_3_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_05_100_3_1_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AR-42	E1504_05_100_3_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_05_100_3_1_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TG101348 (SAR302503)	E1504_05_100_3_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_05_100_3_1_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Sirtinol	E1504_05_100_3_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_05_100_3_1_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX2	E1504_05_100_3_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_05_100_3_1_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD2461	E1504_05_100_3_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_05_100_3_1_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_05_100_3_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_05_100_3_1_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_05_100_3_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_05_100_3_1_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 447439	E1504_05_100_3_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_05_100_3_1_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Barasertib (AZD1152-HQPA)	E1504_05_100_3_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_05_100_3_1_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2-Methoxyestradiol (2-MeOE2)	E1504_05_100_3_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_05_100_3_1_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pracinostat (SB939)	E1504_05_100_3_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_05_100_3_1_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Givinostat (ITF2357)	E1504_05_100_3_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_05_100_3_1_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Quercetin	E1504_05_100_3_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_05_100_3_1_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CCT137690	E1504_05_100_3_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_05_100_3_1_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CEP-33779	E1504_05_100_3_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_05_100_3_1_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Romidepsin (FK228, Depsipeptide)	E1504_05_100_3_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_05_100_3_1_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM XL019	E1504_05_100_3_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_05_100_3_1_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_05_100_3_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_05_100_3_1_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_06_100_3_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_06_100_3_2_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Zebularine	E1504_06_100_3_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_06_100_3_2_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OG-L002	E1504_06_100_3_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_06_100_3_2_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM TMP269	E1504_06_100_3_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_06_100_3_2_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ZM 39923 HCl	E1504_06_100_3_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_06_100_3_2_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Veliparib (ABT-888)	E1504_06_100_3_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_06_100_3_2_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CX-6258 HCl	E1504_06_100_3_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_06_100_3_2_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 2,4-Pyridinedicarboxylic Acid	E1504_06_100_3_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_06_100_3_2_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ITSA-1	E1504_06_100_3_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_06_100_3_2_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AGK2	E1504_06_100_3_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_06_100_3_2_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Oxamflatin	E1504_06_100_3_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_06_100_3_2_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_06_100_3_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_06_100_3_2_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_06_100_3_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_06_100_3_2_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM 3-Deazaneplanocin A (DZNeP)	E1504_06_100_3_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_06_100_3_2_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC-CBP30	E1504_06_100_3_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_06_100_3_2_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ004777	E1504_06_100_3_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_06_100_3_2_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SMI-4a	E1504_06_100_3_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_06_100_3_2_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM FG-4592	E1504_06_100_3_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_06_100_3_2_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BMN 673	E1504_06_100_3_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_06_100_3_2_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Garcinol	E1504_06_100_3_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_06_100_3_2_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tranylcypromine hemisulfate	E1504_06_100_3_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_06_100_3_2_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Salermide	E1504_06_100_3_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_06_100_3_2_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suramin 6Na	E1504_06_100_3_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_06_100_3_2_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_06_100_3_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_06_100_3_2_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_06_100_3_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_06_100_3_2_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ-6438	E1504_06_100_3_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_06_100_3_2_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MM-102	E1504_06_100_3_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_06_100_3_2_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM OTX015	E1504_06_100_3_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_06_100_3_2_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX 01294	E1504_06_100_3_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_06_100_3_2_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Panobinostat (LBH589)	E1504_06_100_3_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_06_100_3_2_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM EPZ5676	E1504_06_100_3_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_06_100_3_2_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Splitomicin	E1504_06_100_3_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_06_100_3_2_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid	E1504_06_100_3_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_06_100_3_2_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM MC-1293	E1504_06_100_3_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_06_100_3_2_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-278	E1504_06_100_3_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_06_100_3_2_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_06_100_3_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_06_100_3_2_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_06_100_3_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_06_100_3_2_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM C646	E1504_06_100_3_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_06_100_3_2_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGI-1027	E1504_06_100_3_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_06_100_3_2_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC669	E1504_06_100_3_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_06_100_3_2_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UPF 1069	E1504_06_100_3_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_06_100_3_2_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Trichostatin A (TSA)	E1504_06_100_3_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_06_100_3_2_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM GSK J4 HCl	E1504_06_100_3_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_06_100_3_2_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-210	E1504_06_100_3_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_06_100_3_2_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nicotinamide	E1504_06_100_3_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_06_100_3_2_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Anacardic acid	E1504_06_100_3_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_06_100_3_2_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NCH-51	E1504_06_100_3_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_06_100_3_2_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_06_100_3_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_06_100_3_2_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_06_100_3_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_06_100_3_2_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM I-BET-762	E1504_06_100_3_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_06_100_3_2_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RG2833 (RGFP109)	E1504_06_100_3_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_06_100_3_2_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM ME0328	E1504_06_100_3_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_06_100_3_2_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Scriptaid	E1504_06_100_3_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_06_100_3_2_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Vorinostat (SAHA, MK0683)	E1504_06_100_3_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_06_100_3_2_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM SGC 0946	E1504_06_100_3_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_06_100_3_2_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Apicidin	E1504_06_100_3_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_06_100_3_2_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-266	E1504_06_100_3_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_06_100_3_2_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM B2	E1504_06_100_3_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_06_100_3_2_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM NSC-3852	E1504_06_100_3_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_06_100_3_2_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_06_100_3_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_06_100_3_2_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_06_100_3_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_06_100_3_2_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RGFP966	E1504_06_100_3_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_06_100_3_2_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM RVX-208	E1504_06_100_3_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_06_100_3_2_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nexturastat A	E1504_06_100_3_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_06_100_3_2_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Tubastatin A	E1504_06_100_3_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_06_100_3_2_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM VX-680 (Tozasertib, MK-0457)	E1504_06_100_3_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_06_100_3_2_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM UNC1215	E1504_06_100_3_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_06_100_3_2_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Suberoyl bis-hydroxamic acid	E1504_06_100_3_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_06_100_3_2_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Piceatannol	E1504_06_100_3_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_06_100_3_2_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BIX-01294 3HCl	E1504_06_100_3_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_06_100_3_2_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Aminoresveratrol sulfate	E1504_06_100_3_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_06_100_3_2_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_06_100_3_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_06_100_3_2_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_06_100_3_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_06_100_3_2_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Bromosporine	E1504_06_100_3_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_06_100_3_2_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM PJ34 HCl	E1504_06_100_3_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_06_100_3_2_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Filgotinib (GLPG0634)	E1504_06_100_3_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_06_100_3_2_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Lomeguatrib	E1504_06_100_3_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_06_100_3_2_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Entinostat (MS-275)	E1504_06_100_3_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_06_100_3_2_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM AZD1208	E1504_06_100_3_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_06_100_3_2_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Nullscript	E1504_06_100_3_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_06_100_3_2_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Fluoro-SAHA	E1504_06_100_3_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_06_100_3_2_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Butyrolactone 3	E1504_06_100_3_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_06_100_3_2_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM BML-281	E1504_06_100_3_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_06_100_3_2_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_06_100_3_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_06_100_3_2_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_06_100_3_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_06_100_3_2_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM IOX1	E1504_06_100_3_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_06_100_3_2_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CPI-203	E1504_06_100_3_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_06_100_3_2_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Rocilinostat (ACY-1215)	E1504_06_100_3_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_06_100_3_2_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Pacritinib (SB1518)	E1504_06_100_3_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_06_100_3_2_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Olaparib (AZD2281, Ku-0059436)	E1504_06_100_3_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_06_100_3_2_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM (+)-JQ1	E1504_06_100_3_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_06_100_3_2_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Isonicotinamide	E1504_06_100_3_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_06_100_3_2_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Valproic acid hydroxamate	E1504_06_100_3_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_06_100_3_2_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM CTPB	E1504_06_100_3_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_06_100_3_2_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 100 nM Triacetylresveratrol	E1504_06_100_3_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 100 nM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_06_100_3_2_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_06_100_3_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_06_100_3_2_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_07_1_1_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_07_1_1_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Belinostat (PXD101)	E1504_07_1_1_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_07_1_1_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Danusertib (PHA-739358)	E1504_07_1_1_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_07_1_1_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SNS-314 Mesylate	E1504_07_1_1_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_07_1_1_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM JNJ-7706621	E1504_07_1_1_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_07_1_1_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT129202	E1504_07_1_1_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_07_1_1_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-14361	E1504_07_1_1_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_07_1_1_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A HCl	E1504_07_1_1_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_07_1_1_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-907	E1504_07_1_1_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_07_1_1_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CI994 (Tacedinaline)	E1504_07_1_1_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_07_1_1_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entacapone	E1504_07_1_1_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_07_1_1_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_07_1_1_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_07_1_1_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_07_1_1_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_07_1_1_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Iniparib (BSI-201)	E1504_07_1_1_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_07_1_1_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mocetinostat (MGCD0103)	E1504_07_1_1_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_07_1_1_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid sodium salt (Sodium valproate)	E1504_07_1_1_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_07_1_1_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Ruxolitinib (INCB018424)	E1504_07_1_1_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_07_1_1_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Hesperadin	E1504_07_1_1_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_07_1_1_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LY2784544	E1504_07_1_1_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_07_1_1_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NVP-BSK805 2HCl	E1504_07_1_1_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_07_1_1_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MK-5108 (VX-689)	E1504_07_1_1_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_07_1_1_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG108	E1504_07_1_1_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_07_1_1_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sodium Phenylbutyrate	E1504_07_1_1_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_07_1_1_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_07_1_1_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_07_1_1_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_07_1_1_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_07_1_1_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-24781 (Abexinostat)	E1504_07_1_1_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_07_1_1_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SRT1720	E1504_07_1_1_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_07_1_1_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYC116	E1504_07_1_1_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_07_1_1_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resveratrol	E1504_07_1_1_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_07_1_1_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EX 527 (Selisistat)	E1504_07_1_1_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_07_1_1_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1776 free base	E1504_07_1_1_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_07_1_1_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101209	E1504_07_1_1_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_07_1_1_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM M344	E1504_07_1_1_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_07_1_1_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Baricitinib (LY3009104, INCB028050)	E1504_07_1_1_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_07_1_1_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine (2-PCPA) HCl	E1504_07_1_1_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_07_1_1_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_07_1_1_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_07_1_1_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_07_1_1_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_07_1_1_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LAQ824 (Dacinostat)	E1504_07_1_1_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_07_1_1_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM INO-1001	E1504_07_1_1_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_07_1_1_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ENMD-2076	E1504_07_1_1_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_07_1_1_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Droxinostat	E1504_07_1_1_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_07_1_1_1_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Azacitidine	E1504_07_1_1_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_07_1_1_1_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZ 960	E1504_07_1_1_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_07_1_1_1_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resminostat	E1504_07_1_1_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_07_1_1_1_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET151 (GSK1210151A)	E1504_07_1_1_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_07_1_1_1_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WHI-P154	E1504_07_1_1_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_07_1_1_1_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Aminobenzamide	E1504_07_1_1_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_07_1_1_1_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_07_1_1_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_07_1_1_1_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_07_1_1_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_07_1_1_1_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quisinostat (JNJ-26481585)	E1504_07_1_1_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_07_1_1_1_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Alisertib (MLN8237)	E1504_07_1_1_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_07_1_1_1_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-101	E1504_07_1_1_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_07_1_1_1_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aurora A Inhibitor I	E1504_07_1_1_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_07_1_1_1_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-34051	E1504_07_1_1_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_07_1_1_1_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYT387	E1504_07_1_1_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_07_1_1_1_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TAK-901	E1504_07_1_1_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_07_1_1_1_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550,Tasocitinib)	E1504_07_1_1_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_07_1_1_1_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34	E1504_07_1_1_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_07_1_1_1_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Procainamide HCl	E1504_07_1_1_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_07_1_1_1_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_07_1_1_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_07_1_1_1_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_07_1_1_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_07_1_1_1_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rucaparib (AG-014699,PF-01367338)	E1504_07_1_1_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_07_1_1_1_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AT9283	E1504_07_1_1_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_07_1_1_1_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Decitabine	E1504_07_1_1_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_07_1_1_1_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PHA-680632	E1504_07_1_1_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_07_1_1_1_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM KW-2449	E1504_07_1_1_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_07_1_1_1_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubacin	E1504_07_1_1_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_07_1_1_1_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AMG-900	E1504_07_1_1_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_07_1_1_1_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WP1066	E1504_07_1_1_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_07_1_1_1_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM S-Ruxolitinib (INCB018424)	E1504_07_1_1_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_07_1_1_1_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550) Citrate	E1504_07_1_1_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_07_1_1_1_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_07_1_1_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_07_1_1_1_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_07_1_1_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_07_1_1_1_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MLN8054	E1504_07_1_1_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_07_1_1_1_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-490 (Tyrphostin B42)	E1504_07_1_1_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_07_1_1_1_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PFI-1 (PF-6405761)	E1504_07_1_1_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_07_1_1_1_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC1568	E1504_07_1_1_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_07_1_1_1_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1480	E1504_07_1_1_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_07_1_1_1_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AR-42	E1504_07_1_1_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_07_1_1_1_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101348 (SAR302503)	E1504_07_1_1_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_07_1_1_1_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sirtinol	E1504_07_1_1_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_07_1_1_1_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX2	E1504_07_1_1_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_07_1_1_1_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD2461	E1504_07_1_1_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_07_1_1_1_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_07_1_1_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_07_1_1_1_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_07_1_1_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_07_1_1_1_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 447439	E1504_07_1_1_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_07_1_1_1_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Barasertib (AZD1152-HQPA)	E1504_07_1_1_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_07_1_1_1_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2-Methoxyestradiol (2-MeOE2)	E1504_07_1_1_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_07_1_1_1_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pracinostat (SB939)	E1504_07_1_1_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_07_1_1_1_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Givinostat (ITF2357)	E1504_07_1_1_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_07_1_1_1_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quercetin	E1504_07_1_1_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_07_1_1_1_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT137690	E1504_07_1_1_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_07_1_1_1_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CEP-33779	E1504_07_1_1_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_07_1_1_1_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Romidepsin (FK228, Depsipeptide)	E1504_07_1_1_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_07_1_1_1_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM XL019	E1504_07_1_1_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_07_1_1_1_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_07_1_1_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_07_1_1_1_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_08_1_1_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_08_1_1_2_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Zebularine	E1504_08_1_1_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_08_1_1_2_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OG-L002	E1504_08_1_1_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_08_1_1_2_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TMP269	E1504_08_1_1_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_08_1_1_2_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 39923 HCl	E1504_08_1_1_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_08_1_1_2_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Veliparib (ABT-888)	E1504_08_1_1_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_08_1_1_2_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CX-6258 HCl	E1504_08_1_1_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_08_1_1_2_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2,4-Pyridinedicarboxylic Acid	E1504_08_1_1_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_08_1_1_2_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ITSA-1	E1504_08_1_1_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_08_1_1_2_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AGK2	E1504_08_1_1_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_08_1_1_2_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Oxamflatin	E1504_08_1_1_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_08_1_1_2_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_08_1_1_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_08_1_1_2_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_08_1_1_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_08_1_1_2_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Deazaneplanocin A (DZNeP)	E1504_08_1_1_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_08_1_1_2_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC-CBP30	E1504_08_1_1_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_08_1_1_2_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ004777	E1504_08_1_1_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_08_1_1_2_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SMI-4a	E1504_08_1_1_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_08_1_1_2_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM FG-4592	E1504_08_1_1_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_08_1_1_2_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BMN 673	E1504_08_1_1_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_08_1_1_2_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Garcinol	E1504_08_1_1_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_08_1_1_2_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine hemisulfate	E1504_08_1_1_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_08_1_1_2_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Salermide	E1504_08_1_1_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_08_1_1_2_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suramin 6Na	E1504_08_1_1_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_08_1_1_2_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_08_1_1_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_08_1_1_2_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_08_1_1_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_08_1_1_2_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ-6438	E1504_08_1_1_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_08_1_1_2_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MM-102	E1504_08_1_1_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_08_1_1_2_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OTX015	E1504_08_1_1_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_08_1_1_2_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX 01294	E1504_08_1_1_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_08_1_1_2_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Panobinostat (LBH589)	E1504_08_1_1_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_08_1_1_2_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ5676	E1504_08_1_1_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_08_1_1_2_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Splitomicin	E1504_08_1_1_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_08_1_1_2_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid	E1504_08_1_1_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_08_1_1_2_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC-1293	E1504_08_1_1_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_08_1_1_2_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-278	E1504_08_1_1_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_08_1_1_2_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_08_1_1_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_08_1_1_2_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_08_1_1_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_08_1_1_2_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM C646	E1504_08_1_1_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_08_1_1_2_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1027	E1504_08_1_1_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_08_1_1_2_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC669	E1504_08_1_1_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_08_1_1_2_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UPF 1069	E1504_08_1_1_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_08_1_1_2_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Trichostatin A (TSA)	E1504_08_1_1_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_08_1_1_2_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM GSK J4 HCl	E1504_08_1_1_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_08_1_1_2_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-210	E1504_08_1_1_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_08_1_1_2_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nicotinamide	E1504_08_1_1_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_08_1_1_2_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Anacardic acid	E1504_08_1_1_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_08_1_1_2_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NCH-51	E1504_08_1_1_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_08_1_1_2_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_08_1_1_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_08_1_1_2_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_08_1_1_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_08_1_1_2_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET-762	E1504_08_1_1_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_08_1_1_2_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG2833 (RGFP109)	E1504_08_1_1_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_08_1_1_2_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ME0328	E1504_08_1_1_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_08_1_1_2_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Scriptaid	E1504_08_1_1_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_08_1_1_2_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Vorinostat (SAHA, MK0683)	E1504_08_1_1_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_08_1_1_2_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC 0946	E1504_08_1_1_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_08_1_1_2_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Apicidin	E1504_08_1_1_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_08_1_1_2_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-266	E1504_08_1_1_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_08_1_1_2_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM B2	E1504_08_1_1_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_08_1_1_2_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NSC-3852	E1504_08_1_1_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_08_1_1_2_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_08_1_1_2_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_08_1_1_2_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_08_1_1_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_08_1_1_2_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RGFP966	E1504_08_1_1_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_08_1_1_2_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RVX-208	E1504_08_1_1_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_08_1_1_2_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nexturastat A	E1504_08_1_1_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_08_1_1_2_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A	E1504_08_1_1_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_08_1_1_2_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM VX-680 (Tozasertib, MK-0457)	E1504_08_1_1_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_08_1_1_2_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC1215	E1504_08_1_1_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_08_1_1_2_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suberoyl bis-hydroxamic acid	E1504_08_1_1_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_08_1_1_2_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Piceatannol	E1504_08_1_1_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_08_1_1_2_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX-01294 3HCl	E1504_08_1_1_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_08_1_1_2_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aminoresveratrol sulfate	E1504_08_1_1_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_08_1_1_2_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_08_1_1_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_08_1_1_2_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_08_1_1_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_08_1_1_2_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Bromosporine	E1504_08_1_1_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_08_1_1_2_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34 HCl	E1504_08_1_1_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_08_1_1_2_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Filgotinib (GLPG0634)	E1504_08_1_1_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_08_1_1_2_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Lomeguatrib	E1504_08_1_1_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_08_1_1_2_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entinostat (MS-275)	E1504_08_1_1_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_08_1_1_2_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1208	E1504_08_1_1_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_08_1_1_2_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nullscript	E1504_08_1_1_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_08_1_1_2_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Fluoro-SAHA	E1504_08_1_1_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_08_1_1_2_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Butyrolactone 3	E1504_08_1_1_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_08_1_1_2_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-281	E1504_08_1_1_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_08_1_1_2_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_08_1_1_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_08_1_1_2_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_08_1_1_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_08_1_1_2_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX1	E1504_08_1_1_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_08_1_1_2_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CPI-203	E1504_08_1_1_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_08_1_1_2_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rocilinostat (ACY-1215)	E1504_08_1_1_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_08_1_1_2_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pacritinib (SB1518)	E1504_08_1_1_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_08_1_1_2_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Olaparib (AZD2281, Ku-0059436)	E1504_08_1_1_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_08_1_1_2_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM (+)-JQ1	E1504_08_1_1_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_08_1_1_2_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Isonicotinamide	E1504_08_1_1_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_08_1_1_2_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid hydroxamate	E1504_08_1_1_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_08_1_1_2_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CTPB	E1504_08_1_1_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_08_1_1_2_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Triacetylresveratrol	E1504_08_1_1_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_08_1_1_2_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_08_1_1_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_08_1_1_2_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_09_1_2_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_09_1_2_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Belinostat (PXD101)	E1504_09_1_2_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_09_1_2_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Danusertib (PHA-739358)	E1504_09_1_2_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_09_1_2_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SNS-314 Mesylate	E1504_09_1_2_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_09_1_2_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM JNJ-7706621	E1504_09_1_2_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_09_1_2_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT129202	E1504_09_1_2_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_09_1_2_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-14361	E1504_09_1_2_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_09_1_2_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A HCl	E1504_09_1_2_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_09_1_2_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-907	E1504_09_1_2_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_09_1_2_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CI994 (Tacedinaline)	E1504_09_1_2_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_09_1_2_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entacapone	E1504_09_1_2_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_09_1_2_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_09_1_2_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_09_1_2_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_09_1_2_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_09_1_2_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Iniparib (BSI-201)	E1504_09_1_2_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_09_1_2_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mocetinostat (MGCD0103)	E1504_09_1_2_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_09_1_2_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid sodium salt (Sodium valproate)	E1504_09_1_2_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_09_1_2_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Ruxolitinib (INCB018424)	E1504_09_1_2_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_09_1_2_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Hesperadin	E1504_09_1_2_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_09_1_2_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LY2784544	E1504_09_1_2_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_09_1_2_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NVP-BSK805 2HCl	E1504_09_1_2_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_09_1_2_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MK-5108 (VX-689)	E1504_09_1_2_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_09_1_2_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG108	E1504_09_1_2_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_09_1_2_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sodium Phenylbutyrate	E1504_09_1_2_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_09_1_2_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_09_1_2_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_09_1_2_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_09_1_2_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_09_1_2_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-24781 (Abexinostat)	E1504_09_1_2_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_09_1_2_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SRT1720	E1504_09_1_2_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_09_1_2_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYC116	E1504_09_1_2_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_09_1_2_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resveratrol	E1504_09_1_2_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_09_1_2_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EX 527 (Selisistat)	E1504_09_1_2_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_09_1_2_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1776 free base	E1504_09_1_2_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_09_1_2_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101209	E1504_09_1_2_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_09_1_2_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM M344	E1504_09_1_2_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_09_1_2_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Baricitinib (LY3009104, INCB028050)	E1504_09_1_2_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_09_1_2_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine (2-PCPA) HCl	E1504_09_1_2_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_09_1_2_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_09_1_2_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_09_1_2_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_09_1_2_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_09_1_2_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LAQ824 (Dacinostat)	E1504_09_1_2_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_09_1_2_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM INO-1001	E1504_09_1_2_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_09_1_2_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ENMD-2076	E1504_09_1_2_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_09_1_2_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Droxinostat	E1504_09_1_2_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_09_1_2_1_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Azacitidine	E1504_09_1_2_1_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Azacitidine in position D06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_E1504_09_1_2_1_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZ 960	E1504_09_1_2_1_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZ 960 in position D07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_E1504_09_1_2_1_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resminostat	E1504_09_1_2_1_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resminostat in position D08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_E1504_09_1_2_1_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET151 (GSK1210151A)	E1504_09_1_2_1_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET151 (GSK1210151A) in position D09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_E1504_09_1_2_1_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WHI-P154	E1504_09_1_2_1_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WHI-P154 in position D10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_E1504_09_1_2_1_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Aminobenzamide	E1504_09_1_2_1_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Aminobenzamide in position D11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_E1504_09_1_2_1_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_09_1_2_1_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_E1504_09_1_2_1_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_09_1_2_1_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_E1504_09_1_2_1_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quisinostat (JNJ-26481585)	E1504_09_1_2_1_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quisinostat (JNJ-26481585) in position E02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_E1504_09_1_2_1_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Alisertib (MLN8237)	E1504_09_1_2_1_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Alisertib (MLN8237) in position E03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_E1504_09_1_2_1_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-101	E1504_09_1_2_1_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-101 in position E04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_E1504_09_1_2_1_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aurora A Inhibitor I	E1504_09_1_2_1_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aurora A Inhibitor I in position E05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_E1504_09_1_2_1_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-34051	E1504_09_1_2_1_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-34051 in position E06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_E1504_09_1_2_1_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYT387	E1504_09_1_2_1_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYT387 in position E07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_E1504_09_1_2_1_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TAK-901	E1504_09_1_2_1_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TAK-901 in position E08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_E1504_09_1_2_1_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550,Tasocitinib)	E1504_09_1_2_1_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550,Tasocitinib) in position E09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_E1504_09_1_2_1_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34	E1504_09_1_2_1_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 in position E10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_E1504_09_1_2_1_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Procainamide HCl	E1504_09_1_2_1_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Procainamide HCl in position E11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_E1504_09_1_2_1_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_09_1_2_1_E12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_60_E1504_01_100_1_1_E12_TAGGATGA_E1504_09_1_2_1_E12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_09_1_2_1_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_E1504_09_1_2_1_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rucaparib (AG-014699,PF-01367338)	E1504_09_1_2_1_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rucaparib (AG-014699,PF-01367338) in position F02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_E1504_09_1_2_1_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AT9283	E1504_09_1_2_1_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AT9283 in position F03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_E1504_09_1_2_1_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Decitabine	E1504_09_1_2_1_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Decitabine in position F04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_E1504_09_1_2_1_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PHA-680632	E1504_09_1_2_1_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PHA-680632 in position F05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_E1504_09_1_2_1_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM KW-2449	E1504_09_1_2_1_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM KW-2449 in position F06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_E1504_09_1_2_1_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubacin	E1504_09_1_2_1_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubacin in position F07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_E1504_09_1_2_1_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AMG-900	E1504_09_1_2_1_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AMG-900 in position F08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_E1504_09_1_2_1_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM WP1066	E1504_09_1_2_1_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM WP1066 in position F09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_E1504_09_1_2_1_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM S-Ruxolitinib (INCB018424)	E1504_09_1_2_1_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM S-Ruxolitinib (INCB018424) in position F10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_E1504_09_1_2_1_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tofacitinib (CP-690550) Citrate	E1504_09_1_2_1_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tofacitinib (CP-690550) Citrate in position F11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_E1504_09_1_2_1_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_09_1_2_1_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_E1504_09_1_2_1_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_09_1_2_1_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_E1504_09_1_2_1_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MLN8054	E1504_09_1_2_1_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MLN8054 in position G02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_E1504_09_1_2_1_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-490 (Tyrphostin B42)	E1504_09_1_2_1_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-490 (Tyrphostin B42) in position G03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_E1504_09_1_2_1_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PFI-1 (PF-6405761)	E1504_09_1_2_1_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PFI-1 (PF-6405761) in position G04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_E1504_09_1_2_1_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC1568	E1504_09_1_2_1_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC1568 in position G05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_E1504_09_1_2_1_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1480	E1504_09_1_2_1_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1480 in position G06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_E1504_09_1_2_1_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AR-42	E1504_09_1_2_1_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AR-42 in position G07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_E1504_09_1_2_1_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101348 (SAR302503)	E1504_09_1_2_1_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101348 (SAR302503) in position G08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_E1504_09_1_2_1_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sirtinol	E1504_09_1_2_1_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sirtinol in position G09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_E1504_09_1_2_1_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX2	E1504_09_1_2_1_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX2 in position G10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_E1504_09_1_2_1_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD2461	E1504_09_1_2_1_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD2461 in position G11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_E1504_09_1_2_1_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_09_1_2_1_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_E1504_09_1_2_1_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_09_1_2_1_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_E1504_09_1_2_1_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 447439	E1504_09_1_2_1_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 447439 in position H02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_E1504_09_1_2_1_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Barasertib (AZD1152-HQPA)	E1504_09_1_2_1_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Barasertib (AZD1152-HQPA) in position H03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_E1504_09_1_2_1_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2-Methoxyestradiol (2-MeOE2)	E1504_09_1_2_1_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2-Methoxyestradiol (2-MeOE2) in position H04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_E1504_09_1_2_1_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pracinostat (SB939)	E1504_09_1_2_1_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pracinostat (SB939) in position H05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_E1504_09_1_2_1_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Givinostat (ITF2357)	E1504_09_1_2_1_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Givinostat (ITF2357) in position H06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_E1504_09_1_2_1_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Quercetin	E1504_09_1_2_1_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Quercetin in position H07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_E1504_09_1_2_1_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT137690	E1504_09_1_2_1_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT137690 in position H08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_E1504_09_1_2_1_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CEP-33779	E1504_09_1_2_1_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CEP-33779 in position H09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_E1504_09_1_2_1_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Romidepsin (FK228, Depsipeptide)	E1504_09_1_2_1_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Romidepsin (FK228, Depsipeptide) in position H10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_E1504_09_1_2_1_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM XL019	E1504_09_1_2_1_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM XL019 in position H11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_E1504_09_1_2_1_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_09_1_2_1_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_E1504_09_1_2_1_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_10_1_2_2_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_last_E1504_10_1_2_2_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Zebularine	E1504_10_1_2_2_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Zebularine in position A02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_last_E1504_10_1_2_2_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OG-L002	E1504_10_1_2_2_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OG-L002 in position A03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_last_E1504_10_1_2_2_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TMP269	E1504_10_1_2_2_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TMP269 in position A04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_last_E1504_10_1_2_2_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ZM 39923 HCl	E1504_10_1_2_2_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ZM 39923 HCl in position A05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_last_E1504_10_1_2_2_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Veliparib (ABT-888)	E1504_10_1_2_2_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Veliparib (ABT-888) in position A06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_last_E1504_10_1_2_2_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CX-6258 HCl	E1504_10_1_2_2_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CX-6258 HCl in position A07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_last_E1504_10_1_2_2_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 2,4-Pyridinedicarboxylic Acid	E1504_10_1_2_2_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 2,4-Pyridinedicarboxylic Acid in position A08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_last_E1504_10_1_2_2_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ITSA-1	E1504_10_1_2_2_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ITSA-1 in position A09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_last_E1504_10_1_2_2_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AGK2	E1504_10_1_2_2_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AGK2 in position A10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_last_E1504_10_1_2_2_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Oxamflatin	E1504_10_1_2_2_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Oxamflatin in position A11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_last_E1504_10_1_2_2_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_10_1_2_2_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_last_E1504_10_1_2_2_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_10_1_2_2_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_last_E1504_10_1_2_2_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM 3-Deazaneplanocin A (DZNeP)	E1504_10_1_2_2_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM 3-Deazaneplanocin A (DZNeP) in position B02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_last_E1504_10_1_2_2_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC-CBP30	E1504_10_1_2_2_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC-CBP30 in position B03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_last_E1504_10_1_2_2_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ004777	E1504_10_1_2_2_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ004777 in position B04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_last_E1504_10_1_2_2_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SMI-4a	E1504_10_1_2_2_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SMI-4a in position B05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_last_E1504_10_1_2_2_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM FG-4592	E1504_10_1_2_2_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM FG-4592 in position B06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_last_E1504_10_1_2_2_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BMN 673	E1504_10_1_2_2_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BMN 673 in position B07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_last_E1504_10_1_2_2_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Garcinol	E1504_10_1_2_2_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Garcinol in position B08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_last_E1504_10_1_2_2_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine hemisulfate	E1504_10_1_2_2_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine hemisulfate in position B09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_last_E1504_10_1_2_2_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Salermide	E1504_10_1_2_2_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Salermide in position B10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_last_E1504_10_1_2_2_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suramin 6Na	E1504_10_1_2_2_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suramin·6Na in position B11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_last_E1504_10_1_2_2_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_10_1_2_2_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_last_E1504_10_1_2_2_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_10_1_2_2_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_last_E1504_10_1_2_2_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ-6438	E1504_10_1_2_2_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ-6438 in position C02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_last_E1504_10_1_2_2_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MM-102	E1504_10_1_2_2_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MM-102 in position C03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_last_E1504_10_1_2_2_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM OTX015	E1504_10_1_2_2_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM OTX015 in position C04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_last_E1504_10_1_2_2_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX 01294	E1504_10_1_2_2_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX 01294 in position C05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_last_E1504_10_1_2_2_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Panobinostat (LBH589)	E1504_10_1_2_2_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Panobinostat (LBH589) in position C06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_last_E1504_10_1_2_2_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EPZ5676	E1504_10_1_2_2_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EPZ5676 in position C07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_last_E1504_10_1_2_2_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Splitomicin	E1504_10_1_2_2_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Splitomicin in position C08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_last_E1504_10_1_2_2_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid	E1504_10_1_2_2_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid in position C09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_last_E1504_10_1_2_2_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MC-1293	E1504_10_1_2_2_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MC-1293 in position C10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_last_E1504_10_1_2_2_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-278	E1504_10_1_2_2_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-278 in position C11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_last_E1504_10_1_2_2_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_10_1_2_2_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_last_E1504_10_1_2_2_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_10_1_2_2_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_last_E1504_10_1_2_2_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM C646	E1504_10_1_2_2_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM C646 in position D02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_last_E1504_10_1_2_2_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1027	E1504_10_1_2_2_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1027 in position D03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_last_E1504_10_1_2_2_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC669	E1504_10_1_2_2_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC669 in position D04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_last_E1504_10_1_2_2_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UPF 1069	E1504_10_1_2_2_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UPF 1069 in position D05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_last_E1504_10_1_2_2_D05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Trichostatin A (TSA)	E1504_10_1_2_2_D06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Trichostatin A (TSA) in position D06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_42_E1504_01_100_1_1_D06_CGCATACA_last_E1504_10_1_2_2_D06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM GSK J4 HCl	E1504_10_1_2_2_D07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM GSK J4 HCl in position D07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_43_E1504_01_100_1_1_D07_CTCAATGA_last_E1504_10_1_2_2_D07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-210	E1504_10_1_2_2_D08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-210 in position D08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_44_E1504_01_100_1_1_D08_CTGAGCCA_last_E1504_10_1_2_2_D08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nicotinamide	E1504_10_1_2_2_D09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nicotinamide in position D09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_45_E1504_01_100_1_1_D09_CTGGCATA_last_E1504_10_1_2_2_D09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Anacardic acid	E1504_10_1_2_2_D10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Anacardic acid in position D10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_46_E1504_01_100_1_1_D10_GAATCTGA_last_E1504_10_1_2_2_D10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NCH-51	E1504_10_1_2_2_D11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NCH-51 in position D11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_47_E1504_01_100_1_1_D11_GACTAGTA_last_E1504_10_1_2_2_D11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_10_1_2_2_D12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_48_E1504_01_100_1_1_D12_GAGCTGAA_last_E1504_10_1_2_2_D12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_10_1_2_2_E01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_49_E1504_01_100_1_1_E01_GATAGACA_last_E1504_10_1_2_2_E01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM I-BET-762	E1504_10_1_2_2_E02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM I-BET-762 in position E02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_50_E1504_01_100_1_1_E02_GCCACATA_last_E1504_10_1_2_2_E02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG2833 (RGFP109)	E1504_10_1_2_2_E03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG2833 (RGFP109) in position E03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_51_E1504_01_100_1_1_E03_GCGAGTAA_last_E1504_10_1_2_2_E03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ME0328	E1504_10_1_2_2_E04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ME0328 in position E04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_52_E1504_01_100_1_1_E04_GCTAACGA_last_E1504_10_1_2_2_E04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Scriptaid	E1504_10_1_2_2_E05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Scriptaid in position E05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_53_E1504_01_100_1_1_E05_GCTCGGTA_last_E1504_10_1_2_2_E05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Vorinostat (SAHA, MK0683)	E1504_10_1_2_2_E06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Vorinostat (SAHA, MK0683) in position E06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_54_E1504_01_100_1_1_E06_GGAGAACA_last_E1504_10_1_2_2_E06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGC 0946	E1504_10_1_2_2_E07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGC 0946 in position E07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_55_E1504_01_100_1_1_E07_GGTGCGAA_last_E1504_10_1_2_2_E07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Apicidin	E1504_10_1_2_2_E08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Apicidin in position E08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_56_E1504_01_100_1_1_E08_GTACGCAA_last_E1504_10_1_2_2_E08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-266	E1504_10_1_2_2_E09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-266 in position E09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_57_E1504_01_100_1_1_E09_GTCGTAGA_last_E1504_10_1_2_2_E09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM B2	E1504_10_1_2_2_E10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM B2 in position E10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_58_E1504_01_100_1_1_E10_GTCTGTCA_last_E1504_10_1_2_2_E10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NSC-3852	E1504_10_1_2_2_E11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NSC-3852 in position E11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_59_E1504_01_100_1_1_E11_GTGTTCTA_last_E1504_10_1_2_2_E11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_10_1_2_2_F01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_61_E1504_01_100_1_1_F01_TATCAGCA_last_E1504_10_1_2_2_F01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RGFP966	E1504_10_1_2_2_F02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RGFP966 in position F02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_62_E1504_01_100_1_1_F02_TCCGTCTA_last_E1504_10_1_2_2_F02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RVX-208	E1504_10_1_2_2_F03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RVX-208 in position F03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_63_E1504_01_100_1_1_F03_TCTTCACA_last_E1504_10_1_2_2_F03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nexturastat A	E1504_10_1_2_2_F04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nexturastat A in position F04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_64_E1504_01_100_1_1_F04_TGAAGAGA_last_E1504_10_1_2_2_F04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A	E1504_10_1_2_2_F05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A in position F05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_65_E1504_01_100_1_1_F05_TGGAACAA_last_E1504_10_1_2_2_F05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM VX-680 (Tozasertib, MK-0457)	E1504_10_1_2_2_F06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM VX-680 (Tozasertib, MK-0457) in position F06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_66_E1504_01_100_1_1_F06_TGGCTTCA_last_E1504_10_1_2_2_F06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM UNC1215	E1504_10_1_2_2_F07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM UNC1215 in position F07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_67_E1504_01_100_1_1_F07_TGGTGGTA_last_E1504_10_1_2_2_F07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Suberoyl bis-hydroxamic acid	E1504_10_1_2_2_F08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Suberoyl bis-hydroxamic acid in position F08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_68_E1504_01_100_1_1_F08_TTCACGCA_last_E1504_10_1_2_2_F08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Piceatannol	E1504_10_1_2_2_F09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Piceatannol in position F09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_69_E1504_01_100_1_1_F09_AACTCACC_last_E1504_10_1_2_2_F09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BIX-01294 3HCl	E1504_10_1_2_2_F10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BIX-01294·3HCl in position F10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_70_E1504_01_100_1_1_F10_AAGAGATC_last_E1504_10_1_2_2_F10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Aminoresveratrol sulfate	E1504_10_1_2_2_F11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Aminoresveratrol sulfate in position F11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_71_E1504_01_100_1_1_F11_AAGGACAC_last_E1504_10_1_2_2_F11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_10_1_2_2_F12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_72_E1504_01_100_1_1_F12_AATCCGTC_last_E1504_10_1_2_2_F12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_10_1_2_2_G01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_73_E1504_01_100_1_1_G01_AATGTTGC_last_E1504_10_1_2_2_G01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Bromosporine	E1504_10_1_2_2_G02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Bromosporine in position G02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_74_E1504_01_100_1_1_G02_ACACGACC_last_E1504_10_1_2_2_G02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PJ34 HCl	E1504_10_1_2_2_G03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PJ34 HCl in position G03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_75_E1504_01_100_1_1_G03_ACAGATTC_last_E1504_10_1_2_2_G03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Filgotinib (GLPG0634)	E1504_10_1_2_2_G04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Filgotinib (GLPG0634) in position G04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_76_E1504_01_100_1_1_G04_AGATGTAC_last_E1504_10_1_2_2_G04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Lomeguatrib	E1504_10_1_2_2_G05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Lomeguatrib in position G05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_77_E1504_01_100_1_1_G05_AGCACCTC_last_E1504_10_1_2_2_G05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entinostat (MS-275)	E1504_10_1_2_2_G06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entinostat (MS-275) in position G06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_78_E1504_01_100_1_1_G06_AGCCATGC_last_E1504_10_1_2_2_G06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AZD1208	E1504_10_1_2_2_G07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AZD1208 in position G07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_79_E1504_01_100_1_1_G07_AGGCTAAC_last_E1504_10_1_2_2_G07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Nullscript	E1504_10_1_2_2_G08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Nullscript in position G08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_80_E1504_01_100_1_1_G08_ATAGCGAC_last_E1504_10_1_2_2_G08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Fluoro-SAHA	E1504_10_1_2_2_G09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Fluoro-SAHA in position G09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_81_E1504_01_100_1_1_G09_ATCATTCC_last_E1504_10_1_2_2_G09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Butyrolactone 3	E1504_10_1_2_2_G10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Butyrolactone 3 in position G10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_82_E1504_01_100_1_1_G10_ATTGGCTC_last_E1504_10_1_2_2_G10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM BML-281	E1504_10_1_2_2_G11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM BML-281 in position G11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_83_E1504_01_100_1_1_G11_CAAGGAGC_last_E1504_10_1_2_2_G11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_10_1_2_2_G12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_84_E1504_01_100_1_1_G12_CACCTTAC_last_E1504_10_1_2_2_G12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_10_1_2_2_H01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_85_E1504_01_100_1_1_H01_CCATCCTC_last_E1504_10_1_2_2_H01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM IOX1	E1504_10_1_2_2_H02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM IOX1 in position H02 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_86_E1504_01_100_1_1_H02_CCGACAAC_last_E1504_10_1_2_2_H02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CPI-203	E1504_10_1_2_2_H03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CPI-203 in position H03 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_87_E1504_01_100_1_1_H03_CCTAATCC_last_E1504_10_1_2_2_H03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Rocilinostat (ACY-1215)	E1504_10_1_2_2_H04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Rocilinostat (ACY-1215) in position H04 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_88_E1504_01_100_1_1_H04_CCTCTATC_last_E1504_10_1_2_2_H04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Pacritinib (SB1518)	E1504_10_1_2_2_H05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Pacritinib (SB1518) in position H05 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_89_E1504_01_100_1_1_H05_CGACACAC_last_E1504_10_1_2_2_H05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Olaparib (AZD2281, Ku-0059436)	E1504_10_1_2_2_H06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Olaparib (AZD2281, Ku-0059436) in position H06 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_90_E1504_01_100_1_1_H06_CGGATTGC_last_E1504_10_1_2_2_H06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM (+)-JQ1	E1504_10_1_2_2_H07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM (+)-JQ1 in position H07 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_91_E1504_01_100_1_1_H07_CTAAGGTC_last_E1504_10_1_2_2_H07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Isonicotinamide	E1504_10_1_2_2_H08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Isonicotinamide in position H08 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_92_E1504_01_100_1_1_H08_GAACAGGC_last_E1504_10_1_2_2_H08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid hydroxamate	E1504_10_1_2_2_H09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid hydroxamate in position H09 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_93_E1504_01_100_1_1_H09_GACAGTGC_last_E1504_10_1_2_2_H09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CTPB	E1504_10_1_2_2_H10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CTPB in position H10 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_94_E1504_01_100_1_1_H10_GAGTTAGC_last_E1504_10_1_2_2_H10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Triacetylresveratrol	E1504_10_1_2_2_H11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Triacetylresveratrol in position H11 in plate 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_95_E1504_01_100_1_1_H11_GATGAATC_last_E1504_10_1_2_2_H11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_10_1_2_2_H12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_96_E1504_01_100_1_1_H12_GCCAAGAC_last_E1504_10_1_2_2_H12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_11_1_3_1_A01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_1_E1504_01_100_1_1_A01_ACAAGCTA_E1504_11_1_3_1_A01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Belinostat (PXD101)	E1504_11_1_3_1_A02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Belinostat (PXD101) in position A02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_2_E1504_01_100_1_1_A02_AAACATCG_E1504_11_1_3_1_A02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Danusertib (PHA-739358)	E1504_11_1_3_1_A03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Danusertib (PHA-739358) in position A03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_3_E1504_01_100_1_1_A03_ACATTGGC_E1504_11_1_3_1_A03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SNS-314 Mesylate	E1504_11_1_3_1_A04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SNS-314 Mesylate in position A04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_4_E1504_01_100_1_1_A04_ACCACTGT_E1504_11_1_3_1_A04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM JNJ-7706621	E1504_11_1_3_1_A05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM JNJ-7706621 in position A05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_5_E1504_01_100_1_1_A05_AACGTGAT_E1504_11_1_3_1_A05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CCT129202	E1504_11_1_3_1_A06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CCT129202 in position A06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_6_E1504_01_100_1_1_A06_CGCTGATC_E1504_11_1_3_1_A06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM AG-14361	E1504_11_1_3_1_A07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM AG-14361 in position A07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_7_E1504_01_100_1_1_A07_CAGATCTG_E1504_11_1_3_1_A07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tubastatin A HCl	E1504_11_1_3_1_A08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tubastatin A HCl in position A08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_8_E1504_01_100_1_1_A08_ATGCCTAA_E1504_11_1_3_1_A08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CUDC-907	E1504_11_1_3_1_A09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CUDC-907 in position A09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_9_E1504_01_100_1_1_A09_CTGTAGCC_E1504_11_1_3_1_A09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CI994 (Tacedinaline)	E1504_11_1_3_1_A10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CI994 (Tacedinaline) in position A10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_10_E1504_01_100_1_1_A10_AGTACAAG_E1504_11_1_3_1_A10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Entacapone	E1504_11_1_3_1_A11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Entacapone in position A11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_11_E1504_01_100_1_1_A11_CATCAAGT_E1504_11_1_3_1_A11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PAO	E1504_11_1_3_1_A12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PAO in positions A01, A12, E01 & E12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_12_E1504_01_100_1_1_A12_AGTGGTCA_E1504_11_1_3_1_A12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_11_1_3_1_B01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_13_E1504_01_100_1_1_B01_AACAACCA_E1504_11_1_3_1_B01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Iniparib (BSI-201)	E1504_11_1_3_1_B02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Iniparib (BSI-201) in position B02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_14_E1504_01_100_1_1_B02_AACCGAGA_E1504_11_1_3_1_B02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mocetinostat (MGCD0103)	E1504_11_1_3_1_B03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mocetinostat (MGCD0103) in position B03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_15_E1504_01_100_1_1_B03_AACGCTTA_E1504_11_1_3_1_B03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Valproic acid sodium salt (Sodium valproate)	E1504_11_1_3_1_B04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Valproic acid sodium salt (Sodium valproate) in position B04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_16_E1504_01_100_1_1_B04_AAGACGGA_E1504_11_1_3_1_B04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Ruxolitinib (INCB018424)	E1504_11_1_3_1_B05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Ruxolitinib (INCB018424) in position B05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_17_E1504_01_100_1_1_B05_AAGGTACA_E1504_11_1_3_1_B05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Hesperadin	E1504_11_1_3_1_B06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Hesperadin in position B06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_18_E1504_01_100_1_1_B06_ACACAGAA_E1504_11_1_3_1_B06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LY2784544	E1504_11_1_3_1_B07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LY2784544 in position B07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_19_E1504_01_100_1_1_B07_ACAGCAGA_E1504_11_1_3_1_B07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM NVP-BSK805 2HCl	E1504_11_1_3_1_B08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM NVP-BSK805 2HCl in position B08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_20_E1504_01_100_1_1_B08_ACCTCCAA_E1504_11_1_3_1_B08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM MK-5108 (VX-689)	E1504_11_1_3_1_B09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM MK-5108 (VX-689) in position B09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_21_E1504_01_100_1_1_B09_ACGCTCGA_E1504_11_1_3_1_B09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM RG108	E1504_11_1_3_1_B10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM RG108 in position B10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_22_E1504_01_100_1_1_B10_ACGTATCA_E1504_11_1_3_1_B10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Sodium Phenylbutyrate	E1504_11_1_3_1_B11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Sodium Phenylbutyrate in position B11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_23_E1504_01_100_1_1_B11_ACTATGCA_E1504_11_1_3_1_B11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1:1000 DMSO	E1504_11_1_3_1_B12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1:1000 DMSO in positions B01, B12, F01 & F12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_24_E1504_01_100_1_1_B12_AGAGTCAA_E1504_11_1_3_1_B12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_11_1_3_1_C01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_25_E1504_01_100_1_1_C01_AGATCGCA_E1504_11_1_3_1_C01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM PCI-24781 (Abexinostat)	E1504_11_1_3_1_C02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM PCI-24781 (Abexinostat) in position C02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_26_E1504_01_100_1_1_C02_AGCAGGAA_E1504_11_1_3_1_C02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SRT1720	E1504_11_1_3_1_C03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SRT1720 in position C03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_27_E1504_01_100_1_1_C03_AGTCACTA_E1504_11_1_3_1_C03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM CYC116	E1504_11_1_3_1_C04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM CYC116 in position C04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_28_E1504_01_100_1_1_C04_ATCCTGTA_E1504_11_1_3_1_C04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Resveratrol	E1504_11_1_3_1_C05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Resveratrol in position C05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_29_E1504_01_100_1_1_C05_ATTGAGGA_E1504_11_1_3_1_C05.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM EX 527 (Selisistat)	E1504_11_1_3_1_C06	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM EX 527 (Selisistat) in position C06 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_30_E1504_01_100_1_1_C06_CAACCACA_E1504_11_1_3_1_C06.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM SGI-1776 free base	E1504_11_1_3_1_C07	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM SGI-1776 free base in position C07 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_31_E1504_01_100_1_1_C07_CAAGACTA_E1504_11_1_3_1_C07.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM TG101209	E1504_11_1_3_1_C08	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM TG101209 in position C08 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_32_E1504_01_100_1_1_C08_CAATGGAA_E1504_11_1_3_1_C08.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM M344	E1504_11_1_3_1_C09	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM M344 in position C09 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_33_E1504_01_100_1_1_C09_CACTTCGA_E1504_11_1_3_1_C09.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Baricitinib (LY3009104, INCB028050)	E1504_11_1_3_1_C10	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Baricitinib (LY3009104, INCB028050) in position C10 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_34_E1504_01_100_1_1_C10_CAGCGTTA_E1504_11_1_3_1_C10.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Tranylcypromine (2-PCPA) HCl	E1504_11_1_3_1_C11	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Tranylcypromine (2-PCPA) HCl in position C11 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_35_E1504_01_100_1_1_C11_CATACCAA_E1504_11_1_3_1_C11.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Mirin	E1504_11_1_3_1_C12	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Mirin in positions C01, C12, G01 & G12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_36_E1504_01_100_1_1_C12_CCAGTTCA_E1504_11_1_3_1_C12.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM DNA-PKi	E1504_11_1_3_1_D01	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM DNA-PKi in positions D01, D12, H01 & H12, in plate 1 & 2	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_37_E1504_01_100_1_1_D01_CCGAAGTA_E1504_11_1_3_1_D01.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM LAQ824 (Dacinostat)	E1504_11_1_3_1_D02	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM LAQ824 (Dacinostat) in position D02 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_38_E1504_01_100_1_1_D02_CCGTGAGA_E1504_11_1_3_1_D02.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM INO-1001	E1504_11_1_3_1_D03	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM INO-1001 in position D03 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_39_E1504_01_100_1_1_D03_CCTCCTGA_E1504_11_1_3_1_D03.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM ENMD-2076	E1504_11_1_3_1_D04	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM ENMD-2076 in position D04 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_40_E1504_01_100_1_1_D04_CGAACTTA_E1504_11_1_3_1_D04.fq.gz
K562 ddCas9 RSTP2 clone5 treated with 1 uM Droxinostat	E1504_11_1_3_1_D05	CRISPR/Cas9 mutation readout on the pathway reporters in Sample from drug screen treated with 1 µM Droxinostat in position D05 in plate 1	AMPLICON	GENOMIC	PCR	single	ILLUMINA	NextSeq 500	CRISPR/Cas9 mutation readout on the pathway reporters in different K562 TRIP clone #5, 72 hours after activation the cells were collected and processed with two successive PCRs on the integrated pathway reporters to generate the libraries, spanning the sgRNA target site and the barcode	fastq	6475_41_E1504_01_100_1_1_D05_CGACTGGA_E1504_11_1_3_1_D05.fq.gz
